Deutsche Bank AG Grows Stock Holdings in Janux Therapeutics, Inc. $JANX

Deutsche Bank AG raised its stake in Janux Therapeutics, Inc. (NASDAQ:JANX) by 7.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 99,691 shares of the company’s stock after buying an additional 6,662 shares during the period. Deutsche Bank AG owned about 0.17% of Janux Therapeutics worth $2,692,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Janux Therapeutics by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 2,278,660 shares of the company’s stock valued at $61,524,000 after buying an additional 142,328 shares during the period. US Bancorp DE lifted its position in shares of Janux Therapeutics by 2,402.9% in the 1st quarter. US Bancorp DE now owns 1,727 shares of the company’s stock worth $47,000 after purchasing an additional 1,658 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Janux Therapeutics by 26.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,125 shares of the company’s stock worth $192,000 after purchasing an additional 1,488 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in shares of Janux Therapeutics in the 1st quarter worth approximately $481,000. Finally, Atle Fund Management AB lifted its position in shares of Janux Therapeutics by 18.3% in the 1st quarter. Atle Fund Management AB now owns 46,808 shares of the company’s stock worth $1,264,000 after purchasing an additional 7,235 shares during the period. 75.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Raymond James Financial assumed coverage on shares of Janux Therapeutics in a research report on Friday, July 11th. They issued an “outperform” rating and a $65.00 price target for the company. Piper Sandler started coverage on shares of Janux Therapeutics in a research report on Monday. They set an “overweight” rating and a $42.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $86.90.

Janux Therapeutics Trading Down 3.3%

Shares of Janux Therapeutics stock opened at $24.70 on Wednesday. The firm has a market capitalization of $1.48 billion, a price-to-earnings ratio of -13.72 and a beta of 2.86. Janux Therapeutics, Inc. has a 12-month low of $21.97 and a 12-month high of $71.71. The firm’s 50 day simple moving average is $24.57 and its two-hundred day simple moving average is $28.06.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.07). On average, sell-side analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.